Print E-mail Contact us
Company News
WuXi Biology/HD Biosciences Presented at Webinar of "New Technologies for Target Discovery and Validation"
Shanghai, China – March 1st, 2022
Novel target discovery and validation are the most crucial steps and prerequisites for successful drug development. In WuXi AppTec webinar on Feb. 16th, HDB’s Dr. Shelley Zhang, Head of Exploratory Biology and Immunology, presented the comprehensive target discovery and validation platforms propelled by various new technologies, and extension to the challenging field of immunology and oncology, as well as utilization in multiple new
modalities for drug discovery.
In the presentation, the following topics are introduced:
Comprehensive target discovery and validation platforms propelled by CRISPR and other
new technologies
Gene editing in various human and mouse primary immune cells
TCR-T and CAR-T cell therapy platforms for all-around services, including surface
antigen validation, in vitro and in vivo efficacy and functional assessment
Advanced new modality development in PROTAC/Target Protein Degradation (TPD),
Antibody-oligo conjugate (AOC) and RNA editing (ASO)
Please use the link below to review the video:
HD Biosciences (China) Co.,Ltd
590 Ruiqing Road
Zhangjiang East Campus, Pudong, Shanghai 201201,
Tel: +86 (21) 5116 3700
Fax: +86 (21) 5116 3766
Target Discovery
In vitro Pharmacology
DMPK & Toxicology
In vivo Pharmaclogy
Other Services
Contact Us
HD Biosciences Shanghai HD Biosciences San Diego HD Biosciences New Jersey WeChat
590 Ruiqing Road, 6122 Nancy Ridge Drive 6 Cedarbrook Drive
Pudong, Shanghai, 201201 San Diego, CA, 92121 Cranbury, NJ 08512
China US US
Tel: +86 (21) 5116-3700 Tel: +1 (858) 888-7888 Tel: +1 (609) 606-6680
Email: Email: Email: